Breastfeeding women finally included in TB drug research
NCT ID NCT07069582
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how five common tuberculosis drugs move into breast milk after a single dose. Sixty healthy breastfeeding women in Indonesia will each receive one drug, and researchers will measure drug levels in their blood and milk. The goal is to gather safety data so that breastfeeding women can be included in future TB prevention trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Rifampicin, isoniazid, levofloxacin, rifapentine, and bedaquiline
What this could lead to
If successful, this study could help include breastfeeding women in future TB prevention trials, ensuring safer dosing guidelines for mothers and infants.
What could go wrong
This is an early-phase, single-dose study in healthy volunteers, not patients. Results may not apply to women with TB or to repeated dosing, and drug levels in milk may vary widely.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Universitas Padjadjaran, Klinik Penelitian Tuberculosis (TB Research Clinic)
Bandung, West Java, 40161, Indonesia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact